A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

NCT06007937 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Metastatic
Recurrent

Interventions

DRUG: Lorlatinib
DRUG: Ramucirumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]